BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35131966)

  • 1. Development 68Ga trastuzumab Fab and bioevaluation by PET imaging in HER2/neu expressing breast cancer patients.
    Rathore Y; Shukla J; Laroiya I; Deep A; Lakhanpal T; Kumar R; Singh H; Bal A; Singh G; Gopal Thakur K; Mittal BR
    Nucl Med Commun; 2022 Apr; 43(4):458-467. PubMed ID: 35131966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Breast Cancer Using 177 Lu-Labeled Trastuzumab and Trastuzumab Fragment : First-in-Human Clinical Experience.
    Rathore Y; Lakhanpal T; Chakraborty S; Chakravarty R; Mittal BR; Irrinki RNS; Laroiya I; Kaur K; Shukla J
    Clin Nucl Med; 2024 Jun; 49(6):e258-e265. PubMed ID: 38579266
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Kwon LY; Scollard DA; Reilly RM
    Mol Pharm; 2017 Feb; 14(2):492-501. PubMed ID: 28049295
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Suman SK; Mukherjee A; Pandey U; Chakraborty A; Rakshit S; Tawate M; Sarma HD
    Cancer Biother Radiopharm; 2023 Feb; 38(1):38-50. PubMed ID: 36413344
    [No Abstract]   [Full Text] [Related]  

  • 5. MANOTA: a promising bifunctional chelating agent for copper-64 immunoPET.
    Moreau M; Poty S; Vrigneaud JM; Walker P; Guillemin M; Raguin O; Oudot A; Bernhard C; Goze C; Boschetti F; Collin B; Brunotte F; Denat F
    Dalton Trans; 2017 Oct; 46(42):14659-14668. PubMed ID: 28861553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [(99m)Tc]-HYNIC-trastuzumab (Herceptin) Fab fragments.
    Tang Y; Scollard D; Chen P; Wang J; Holloway C; Reilly RM
    Nucl Med Commun; 2005 May; 26(5):427-32. PubMed ID: 15838425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PET imaging of CD105/endoglin expression with a ⁶¹/⁶⁴Cu-labeled Fab antibody fragment.
    Zhang Y; Hong H; Orbay H; Valdovinos HF; Nayak TR; Theuer CP; Barnhart TE; Cai W
    Eur J Nucl Med Mol Imaging; 2013 May; 40(5):759-67. PubMed ID: 23344138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging.
    Dijkers EC; Kosterink JG; Rademaker AP; Perk LR; van Dongen GA; Bart J; de Jong JR; de Vries EG; Lub-de Hooge MN
    J Nucl Med; 2009 Jun; 50(6):974-81. PubMed ID: 19443585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using (111)In-trastuzumab (Herceptin) Fab fragments.
    Tang Y; Wang J; Scollard DA; Mondal H; Holloway C; Kahn HJ; Reilly RM
    Nucl Med Biol; 2005 Jan; 32(1):51-8. PubMed ID: 15691661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A preliminary clinical trial to evaluate
    Lee I; Lim I; Byun BH; Kim BI; Choi CW; Woo SK; Kim KI; Lee KC; Kang JH; Seong MK; Kim HA; Noh WC; Lim SM
    EJNMMI Res; 2021 Jan; 11(1):8. PubMed ID: 33475899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ImmunoPET of tissue factor expression in triple-negative breast cancer with a radiolabeled antibody Fab fragment.
    Shi S; Hong H; Orbay H; Graves SA; Yang Y; Ohman JD; Liu B; Nickles RJ; Wong HC; Cai W
    Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1295-303. PubMed ID: 25801992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninvasive Detection of HER2 Expression in Gastric Cancer by
    Guo X; Zhu H; Zhou N; Chen Z; Liu T; Liu F; Xu X; Jin H; Shen L; Gao J; Yang Z
    Mol Pharm; 2018 Nov; 15(11):5174-5182. PubMed ID: 30251865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and preclinical studies of
    Lam K; Chan C; Reilly RM
    MAbs; 2017 Jan; 9(1):154-164. PubMed ID: 27813707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A kit to prepare (111)In-DTPA-trastuzumab (Herceptin) Fab fragments injection under GMP conditions for imaging or radioimmunoguided surgery of HER2-positive breast cancer.
    Scollard DA; Chan C; Holloway CM; Reilly RM
    Nucl Med Biol; 2011 Jan; 38(1):129-36. PubMed ID: 21220136
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.